文献速递自身炎症与 IgG4 相关病

VEXAS综合征患者的治疗结局:一项回顾性队列研究

Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study.
PubMed 文献 · Lancet Rheumatol · 2025-05-21

该回顾性队列研究分析了英国59例基因确诊VEXAS综合征患者中71种靶向治疗与单用泼尼松龙的结局,发现6个月时阿扎胞苷和托珠单抗的疗效优于阿那白滞素、巴瑞替尼和单用泼尼松龙,阿扎胞苷的缓解可能性高于其他治疗(风险比2.47,95%CI 1.18-5.20;p=0.018),治疗选择应考虑个体风险因素和耐受性。

要点

  • 6个月时,阿扎胞苷治疗者11例中10例(91%)有应答(完全应答3例[27%]),托珠单抗11例中7例(64%)有应答(完全应答4例[36%])。
  • 阿扎胞苷6个月应答可能性高于其他治疗(风险比2.47,95%CI 1.18-5.20;p=0.018)。
  • 71种治疗中28种(39%)被停用,最常见原因为严重不良事件(12种[17%])和死亡(9种[13%])。

核心结论

  • 在该英国VEXAS综合征队列中,阿扎胞苷和托珠单抗的疗效优于阿那白滞素、巴瑞替尼和单用泼尼松龙。
  • 治疗选择应考虑个体风险因素和耐受性。
  • 需要前瞻性研究确认最佳治疗策略并制定标准化方案。

研究设计与样本

  • 回顾性队列研究,纳入英国6个三级转诊中心2014年7月22日至2024年10月19日期间基因确诊VEXAS综合征且接受至少一种靶向治疗或单用泼尼松龙的患者。
  • 排除基线后所有时间点均无临床信息的患者。
  • 收集诊断时、治疗开始时及治疗开始后3、6、12个月(±28天)的临床和生化数据。
  • 主要结局为完全应答(临床缓解、CRP≤10 mg/L且泼尼松龙≤10 mg/天)和部分应答(临床缓解且CRP和糖皮质激素剂量较基线均降低≥50%)。
  • 共分析59例患者中的71种靶向治疗。

主要发现

  • 59例患者中58例(98%)为男性、1例(2%)为女性,平均年龄71岁(SD 8),27例(46%)患有骨髓增生异常综合征。
  • 治疗包括托珠单抗(n=19)、阿那白滞素(n=13)、阿扎胞苷(n=13)、巴瑞替尼(n=11)和单用泼尼松龙(n=10)。
  • 6个月时,继续治疗者中阿扎胞苷11例中10例(91%)有应答(完全应答3例[27%]),托珠单抗11例中7例(64%)有应答(完全应答4例[36%]),阿那白滞素3例中3例(100%)有应答(完全应答1例[33%]),巴瑞替尼5例中2例(40%)有应答(无完全应答)。
  • 阿扎胞苷6个月应答可能性高于其他治疗(风险比2.47,95%CI 1.18-5.20;p=0.018)。
  • 诊断时无发热或血栓栓塞与更好的结局相关。

关键数值与推荐

  • 完全应答定义为临床缓解、CRP≤10 mg/L且泼尼松龙≤10 mg/天。
  • 部分应答定义为临床缓解且CRP和糖皮质激素剂量较基线均降低≥50%。
  • 阿扎胞苷6个月应答风险比为2.47(95%CI 1.18-5.20;p=0.018),高于其他治疗。

临床怎么用

  • 作者认为,治疗选择应考虑个体风险因素和耐受性。
  • 作者指出,需要前瞻性研究确认最佳治疗策略并制定标准化方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a recently described autoinflammatory disorder with little therapeutic evidence. We compared treatment outcomes of targeted therapies versus prednisolone alone in the largest UK cohort of patients with VEXAS syndrome to date. METHODS: In this retrospective cohort study, we analysed the outcomes of targeted therapies in patients with VEXAS syndrome in six tertiary referral centres across the UK between July 22, 2014, and Oct 19, 2024. The inclusion criteria were genetically confirmed VEXAS syndrome and receipt of at least one targeted therapy or prednisolone alone. Patients without clinical information at all timepoints after baseline were excluded. Data collection forms were used to record clinical and biochemical data at the following timepoints: time of diagnosis, initiation of treatment, and follow-up at 3 months, 6 months, and 12 months from the initiation of treatment (±28 days). Laboratory parameters, including C-reactive protein (CRP) and haemoglobin, and glucocorticoid doses were collected at each timepoint and compared between timepoints. Primary outcomes were complete response (ie, clinical remission, CRP ≤10 mg/L, and prednisolone ≤10 mg per day) and partial response (ie, clinical remission with ≥50% reductions in both CRP and glucocorticoid dose from baseline) to treatment. Treatment discontinuation and adverse events were documented for each treatment. Due to the high prevalence of cytopenias in VEXAS syndrome, these were only recorded as adverse events when necessitating treatment change. People with lived experience were not involved in the study. FINDINGS: We analysed 71 targeted therapies in 59 patients with genetically confirmed VEXAS syndrome. Of the 59 patients, 58 (98%) were male and one (2%) was female, with a mean age of 71 years (SD 8), and 27 (46%) had myelodysplastic syndrome. The treatments included tocilizumab (n=19), anakinra (n=13), azacitidine (n=13), baricitinib (n=11), and prednisolone only (n=10). At 6 months, in those who continued therapy, ten (91%) of 11 patients receiving azacitidine showed a response (three [27%] complete responses), as well as did seven (64%) of 11 receiving tocilizumab (four [36%] complete responses), three (100%) of three receiving anakinra (one [33%] complete response), and two (40%) of five receiving baricitinib (no complete responses). Although all patients who tolerated anakinra had a response, the discontinuation rate was high (eight [62%] of 13), mostly due to severe injection-site reactions (n=5). Patients were more likely to respond to azacitidine than to other therapies at 6 months (risk ratio 2·47, 95% CI 1·18-5·20; p=0·018). Absence of fever or thromboembolism at diagnosis was associated with better outcomes. By 6 months, median CRP concentrations had decreased in patients receiving tocilizumab (from 30 mg/L [IQR 13-45] to 4 mg/L [3-37]) or anakinra (from 18 mg/L [11-52] to 2 mg/L [1-28]), whereas azacitidine showed the greatest increase in haemoglobin (from mean concentration 104 g/L [SD 17·5] to 120 g/L [14·4]). 28 (39%) of 71 treatments were discontinued, most commonly due to serious adverse events (12 [17%]) and death (nine [13%]). Infections were most frequent with azacitidine (eight [62%] of 13) and tocilizumab (nine [47%] of 19). INTERPRETATION: In this UK cohort of patients with VEXAS syndrome, azacitidine and tocilizumab showed superior effectiveness compared with anakinra, baricitinib, and prednisolone only. Treatment selection should consider individual risk factors and tolerability. Prospective studies are needed to confirm optimal treatment strategies and develop standardised protocols. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Al-Hakim A, Trikha R, Phyu Htut EE, et al. Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study. Lancet Rheumatol. 2025. PMID: 40412417. doi:10.1016/S2665-9913(25)00034-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。